000042514 000__ 00919cam\a22003735i\4500
000042514 001__ 42514
000042514 003__ SzGeWIPO
000042514 005__ 20240708145909.0
000042514 006__ m\\\\eo\\d\\\\\\\\
000042514 007__ cr bn |||m|||a
000042514 008__ 210302s2020\\\\enk\\\\\\\\\\\000\0\eng\d
000042514 022__ $$a1747-1540 (online)
000042514 0247_ $$a10.1093/jiplp/jpaa114$$2doi
000042514 035__ $$a(OCoLC)1248937651
000042514 040__ $$aSzGeWIPO$$beng$$erda$$cSzGeWIPO$$dCaBNVSL
000042514 041__ $$aeng
000042514 24500 $$aIP and the supply of COVID-19-related drugs.
000042514 264_1 $$a[Oxford, England] :$$bOxford University Press (OUP),$$c2020.
000042514 300__ $$a[3] pages ;$$c[28] cm
000042514 336__ $$atext$$btxt$$2rdacontent
000042514 337__ $$aunmediated$$bn$$2rdamedia
000042514 338__ $$avolume$$bnc$$2rdacarrier
000042514 500__ $$aJournal of Intellectual Property Law & Practice, 15, 8, 2020, pp. 590-593
000042514 542__ $$fhttps://academic.oup.com/jiplp/article/15/8/590/5882129
000042514 588__ $$aCrossref
000042514 590__ $$aPublished online: 07-Aug-20
000042514 7001_ $$aStothers, Christopher,$$eauthor.
000042514 7001_ $$aMorgan, Alexandra,$$eauthor.
000042514 7730_ $$tJournal of Intellectual Property Law & Practice.$$g15, 8, 2020, pp. 590-593,$$x1747-1532$$wjiplp
000042514 85641 $$uhttps://doi.org/10.1093/jiplp/jpaa114$$yOnline version
000042514 904__ $$aJournal article
000042514 980__ $$aJIPLP